Pipeline

Before a new medicine becomes available to the broad public, it goes through an extensive preclinical and clinical validation process. Below you can find an overview of the various ongoing research projects of ThromboGenics and its research partners.

“Our extensive pipeline of innovative eye medicines gives the company continuity and can make ThromboGenics a prominent player in the market for diabetic eye disease.” -  CEO Dr. Patrik De Haes and Chairman Dr. Staf Van Reet

 

Drug/Target Target Indication
Pre-clinicalClinical
Phase I
Clinical
Phase II
Clinical
Phase III
Go
Milestones
JETREA (ocriplasmin) Symptomatic VMA/VMT
Pre-clinicalClinical
Phase I
Clinical
Phase II
Clinical
Phase III
Go
Commercialized: US (directly)/ ex-US with Alcon
THR-409 (ocriplasmin) Diabetic Retinopathy
Pre-clinicalClinical
Phase I
Clinical
Phase II
Clinical
Phase III
Go
Ocriplasmin for inducing total PVD and halt further progression from Diabetic Retinopathy (DR) to Proliferative Diabetic Retinopathy (PDR).
THR-317 (anti-PIGF) Diabetic Retinopathy
Pre-clinicalClinical
Phase I
Clinical
Phase II
Clinical
Phase III
Go
A PLGF neutralizing monoclonal antibody is developed for DME and/or for use in combination therapy with current anti-VEGF drugs for treatments of DME or DR.
THR-687 (integrin antagonist) Diabetic Retinopathy
Pre-clinicalClinical
Phase I
Clinical
Phase II
Clinical
Phase III
Go
Preparing start Phase I clinical trial - Integrin receptor antagonist for treatment of DR with and without DME.
THR-149 (pKal Inhibitor) Diabetic Retinopathy
Pre-clinicalClinical
Phase I
Clinical
Phase II
Clinical
Phase III
Go
Preparing start Phase I clinical trial – a plasma kallikrein inhibitor to treat DME associated with DR.